Scholarlink

<p>Although the COVID-19 pandemic has officially ended, outbreaks still occur, especially in immunocompromised patients, including those undergoing chimeric antigen receptor T-cell (CAR T-cell) therapy, who have weakened immune systems due to prior treatments or CAR T-related effects such as severe and prolonged neutropenia, lymphopenia and hypogammaglobulinemia. This retrospective study analyzed relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients receiving CAR T-cell therapy, assessing the impact of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on overall survival (OS), progression-free survival (PFS), and delays in leukapheresis and CAR T-cell infusion. Among 89 infused patients, 37 (41.6%) developed COVID-19. Compared to the COVID + cohort, COVID- patients had worse prognostic scores and higher LDH and ferritin levels before infusion. SARS-CoV-2 infection delayed leukapheresis (14–35 days) and CAR T-cell infusion (20–65 days). The best overall response rate (BRR) in the CAR T-cell population was 77.5% (69/89 patients), with a complete response (CR) rate of 67%. The BRR was 100% in COVID + patients vs. 61.5% in COVID−. Median PFS was 5.47 months in the COVID- cohort and not reached in the COVID + cohort (<i>p</i> = 0.007). Median OS was 19 months in COVID- patients and not reached in COVID+ (<i>p</i> &lt; 0.0001). No significant survival differences were found between COVID + and COVID − patients. Improved outcomes likely resulted from widespread vaccination, prophylaxis, early antiviral treatments, and the emergence of less virulent SARS-CoV-2 variants, reducing disease severity and mortality, allowing for better management of these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Marianna Gentilini,
  • Beatrice Casadei,
  • Cinzia Pellegrini,
  • Lisa Argnani,
  • Gabriele Gugliotta,
  • Matteo Carella,
  • Vittorio Stefoni,
  • Nicole Fabbri,
  • Giulia Gabrielli,
  • Flavia Salvatore,
  • Alessandro Desiderio,
  • Camilla Mazzoni,
  • Pierluca Maglio,
  • Gianmarco Bagnato,
  • Alessandro Broccoli,
  • Francesca Bonifazi,
  • Pier Luigi Zinzani

摘要

Although the COVID-19 pandemic has officially ended, outbreaks still occur, especially in immunocompromised patients, including those undergoing chimeric antigen receptor T-cell (CAR T-cell) therapy, who have weakened immune systems due to prior treatments or CAR T-related effects such as severe and prolonged neutropenia, lymphopenia and hypogammaglobulinemia. This retrospective study analyzed relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients receiving CAR T-cell therapy, assessing the impact of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on overall survival (OS), progression-free survival (PFS), and delays in leukapheresis and CAR T-cell infusion. Among 89 infused patients, 37 (41.6%) developed COVID-19. Compared to the COVID + cohort, COVID- patients had worse prognostic scores and higher LDH and ferritin levels before infusion. SARS-CoV-2 infection delayed leukapheresis (14–35 days) and CAR T-cell infusion (20–65 days). The best overall response rate (BRR) in the CAR T-cell population was 77.5% (69/89 patients), with a complete response (CR) rate of 67%. The BRR was 100% in COVID + patients vs. 61.5% in COVID−. Median PFS was 5.47 months in the COVID- cohort and not reached in the COVID + cohort (p = 0.007). Median OS was 19 months in COVID- patients and not reached in COVID+ (p < 0.0001). No significant survival differences were found between COVID + and COVID − patients. Improved outcomes likely resulted from widespread vaccination, prophylaxis, early antiviral treatments, and the emergence of less virulent SARS-CoV-2 variants, reducing disease severity and mortality, allowing for better management of these patients.